LBI-HTA - Publications - Search - Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017 . HSO: 31st Prioritisation.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
138Kb
Abstract

For the 31st prioritisation (May 2017), 10 drugs were filtered out of 302 identified and were sent to prioritisation. Of these, 4 drugs were ranked as 'highly relevant' by the expert panel, 5 as 'relevant' and 1 as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:HSO: 31st Prioritisation
Deposited on:12 May 2017 14:03
Last Modified:24 Aug 2017 15:21

Repository Staff Only: item control page